Indications : התוויות

Therapeutic indications                                              Patients with an increased risk of cardiac toxicity should be           � inspection of the oral cavity and pharynx for mucosal changes          doxorubicin is initiated.                                                Vaccines are not recommended (see section 4.5).
Doxorubicin Teva is indicated for producing regression in                considered for treatment with a 24-hours continuous infusion            � blood tests: haematocrit, platelets, differential white cell count,    Haematologic profiles should be assessed before and during each          Administration of live or live-attenuated vaccines in patients disseminated neoplastic conditions such as: acute lymphoblastic          of single dose, rather than injection. In this way, cardiac toxicity       SGPT, SGOT, LDH, bilirubin, uric acid.                                cycle of therapy with doxorubicin, including differential white blood    immunocompromised by chemotherapeutic agents including leukaemia, acute myeloblastic leukaemia, Wilms’ tumour,                  may be less frequent, without a reduction in therapeutic efficacy.
In these patients, the ejection fraction should be measured             The patient should be informed that the urine might be reddish           cell (WBC) counts. A dose-dependent, reversible leucopenia               doxorubicin, may result in serious or fatal infections. Vaccination neuroblastoma, soft tissue and bone sarcomas, breast                                                                                             after administration.                                                                                                                             with a live vaccine should be avoided in patients receiving carcinoma, lymphomas of both Hodgkin’s and non-Hodgkin’s                 before each course.                                                                                                                              and/or granulocytopenia (neutropenia) is the predominant Nausea, vomiting and mucositis are often extremely severe and            manifestation of doxorubicin haematologic toxicity and is the            doxorubicin. Killed or inactivated vaccines may be administered; types, bronchogenic carcinoma in which the small cell histologic         Patients with limited bone marrow reserve not related to bone                                                                                                                                                             however, the response to such vaccines may be diminished.
type is the most responsive compared to other cell types, and                                                                                    should be prevented and if necessary treated appropriately.              most common acute dose-limiting toxicity of this drug. Leucopenia marrow involvement of the disease                                                                                                                                                                                         During treatment with doxorubicin hydrochloride patients should gastric carcinoma.                                                                                                                               Cardiac function                                                         and neutropenia generally reach the nadir between days 10 and The dosages may be reduced in patients with a history of                                                                                         14 after drug administration; the WBC/neutrophil counts return           avoid contact with recently polio vaccinated persons.